E-therapeutics Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETXPF research report →
About the company
E-therapeutics Plc is a UK-based company focused on drug discovery. The core of its work involves a sophisticated computational platform that employs in-silico screening and unique network models to identify and predict which compounds or biological targets can effectively alter relevant biological processes. Furthermore, the company is advancing an RNA interference (RNAi) platform designed for highly specific gene silencing.
- CEO
- Ahmad Ali Mortazavi
- IPO
- 2020
- Employees
- 39
- HQ
- London, GB
Price Chart
- Market Cap
- $75.96M
- P/E
- -4.71
- P/S
- 177.32
- P/B
- 2.39
- EV/EBITDA
- -2.65
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -4337.74%
- Net Margin
- -3511.32%
- ROE
- -40.58%
- ROIC
- -51.86%
- Revenue
- $0 · -100.00%
- Net Income
- $-14,869,000 · -33.16%
- EPS
- $-0.02 · -5.24%
- Op Income
- $-18,646,000
- FCF YoY
- -52.27%
- 52W High
- $0.13
- 52W Low
- $0.13
- 50D MA
- $0.13
- 200D MA
- $0.13
- Beta
- 0.42
- Avg Volume
- 0
Get TickerSpark's AI analysis on ETXPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ETXPF coverage
Recent articles, reports, and earnings notes.
No research on ETXPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ETXPF report →Similar companies
Peers in the same neighborhood.